MacroGenics, Inc.
MacroGenics, Inc. (MGNX) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
mgnx · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for MacroGenics, Inc. (MGNX) measures how much investors pay for each dollar of the company's trailing earnings. MGNX's current PE ratio of N/A is calculated by dividing its stock price of $3.88 by its TTM earnings per share of -$1.11.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2011 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
MacroGenics, Inc.You MGNX | $247M | N/A | — | -$1.11 |
 Clene Inc. CLNN | $55M | N/A | — | -$2.65 |
 Connect Biopharma Holdings Limited CNTB | $139M | N/A | — | -$1.00 |
 Context Therapeutics Inc. CNTX | $157M | N/A | — | -$0.38 |
 Coya Therapeutics, Inc. COYA | $83M | N/A | — | -$1.27 |
 InflaRx N.V. IFRX | $124M | N/A | — | -$0.68 |
 Oramed Pharmaceuticals Inc. ORMP | $149M | 1.84x | — | $1.55 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-1.18 | — | |
2024-12-31 FY2024 | — | $-1.07 | — | |
2023-12-31 FY2023 | — | $-0.15 | — | |
2022-12-31 FY2022 | — | $-1.95 | — | |
2021-12-31 FY2021 | — | $-3.37 | — | |
2020-12-31 FY2020 | — | $-2.47 | — | |
2019-12-31 FY2019 | — | $-3.16 | — | |
2018-12-31 FY2018 | — | $-4.19 | — | |
2017-12-31 FY2017 | — | $-0.54 | — | |
2016-12-31 FY2016 | — | $-1.69 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for MacroGenics, Inc. (MGNX) measures how much investors pay for each dollar of the company's trailing earnings. MGNX's current PE ratio of N/A is calculated by dividing its stock price of $3.88 by its TTM earnings per share of -$1.11.
Frequently asked questions
MGNX pe ratio · 6 questionsMGNX's current PE ratio is N/A as of 2026-06-09, based on a stock price of $3.88 and TTM EPS of -$1.11. Data sourced from Financial Modeling Prep via MGNX's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · MacroGenics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09